BioMarin Pharmaceutical
Inc. BMRN today announced that the Endocrinologic and Metabolic Drugs
Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA)
voted in favor of approval of Vimizim for the treatment of Morquio A syndrome,
also called Mucopolysaccharidosis Type IVA (MPS IVA). Of the 21 panel members,
19 voted in favor of approval of Vimizim for use in all MPS IVA patients, 1
voted in favor of approval for a subgroup of MPS IVA patients, and one panel
member voted to not recommend approval.
Vimizim is an investigational enzyme replacement therapy for the treatment of
patients with the lysosomal storage disorder Morquio A syndrome. Morquio A
syndrome is an ultra-rare, severely debilitating disease that affects an
estimated 3,000 patients in the developed world.
"We are thrilled to have achieved this important milestone in our mission to
bring the first approved therapy to treat Morquio A patients," said
Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin. "I am very pleased
with the outcome of today's panel vote and look forward to continuing to work
with the FDA to bring this much-needed therapy to these patients."
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of
February 28, 2014, for completion of its review of the Biologics License
Application (BLA) for Vimizim. The EMDAC provides the FDA with independent
expert advice and recommendations. The FDA is not bound by the EMDAC's
recommendation, but will consider the committee's recommendation as the FDA
completes its review of the Vimizim BLA.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in